Patient characteristics
| Characteristic . | No. of patients, N = 113 . |
|---|---|
| Sex, M/F | 65/48 |
| Median age, y (range) | 9 (1-18) |
| Cause of aplastic anemia | |
| Idiopathic | 97 |
| Hepatitis | 15 |
| Drug | 1 |
| Severity of disease at diagnosis | |
| Very severe | 39 |
| Severe | 47 |
| Moderate | 27 |
| Newly diagnosed patients/previously treated patients | 98/15 |
| Median days from diagnosis to treatment in newly diagnosed patients (range) | 22 (1-180) |
| Median months from diagnosis to treatment in previously treated patients (range) | 12 (7-48) |
| Median days of treatment in newly diagnosed patients (range) | |
| G-CSF | 76 (0-839) |
| Cyclosporin | 400 (94-2200) |
| Danazol | 340 (0-1640) |
| Median days of treatment in previously treated patients (range) | |
| G-CSF | 277 (0-1125) |
| Cyclosporin | 350 (145-1950) |
| Danazol | 410 (0-2615) |
| Response to treatment after 6 months | |
| Complete response | 30 |
| Partial response | 31 |
| No response | 42 |
| Number of patients who underwent stem cell transplantation | 27 |
| Number of patients who received second ATG therapy | 17 |
| Number of patients who received G-CSF before registration | 8 |
| Median months of follow-up (range) | 64 (45-107) |
| Characteristic . | No. of patients, N = 113 . |
|---|---|
| Sex, M/F | 65/48 |
| Median age, y (range) | 9 (1-18) |
| Cause of aplastic anemia | |
| Idiopathic | 97 |
| Hepatitis | 15 |
| Drug | 1 |
| Severity of disease at diagnosis | |
| Very severe | 39 |
| Severe | 47 |
| Moderate | 27 |
| Newly diagnosed patients/previously treated patients | 98/15 |
| Median days from diagnosis to treatment in newly diagnosed patients (range) | 22 (1-180) |
| Median months from diagnosis to treatment in previously treated patients (range) | 12 (7-48) |
| Median days of treatment in newly diagnosed patients (range) | |
| G-CSF | 76 (0-839) |
| Cyclosporin | 400 (94-2200) |
| Danazol | 340 (0-1640) |
| Median days of treatment in previously treated patients (range) | |
| G-CSF | 277 (0-1125) |
| Cyclosporin | 350 (145-1950) |
| Danazol | 410 (0-2615) |
| Response to treatment after 6 months | |
| Complete response | 30 |
| Partial response | 31 |
| No response | 42 |
| Number of patients who underwent stem cell transplantation | 27 |
| Number of patients who received second ATG therapy | 17 |
| Number of patients who received G-CSF before registration | 8 |
| Median months of follow-up (range) | 64 (45-107) |
G-CSF indicates granulocyte colony-stimulating factor; ATG, antithymocyte globulin.